Pfizer Drug Pipeline

Pfizer maintains a large and diverse clinical portfolio, with 153 active trials out of 2005 total trials registered since 2008. These active programs span 19 therapeutic areas and multiple phases of development, including 58 in Phase 1, 47 in Phase 2, 62 in Phase 3, and 6 in Phase 4. The portfolio is heavily weighted toward oncology, which accounts for 119 active trials, or approximately 78% of the active programs. Within oncology, the most active indications are solid tumor (advanced) with 21 active trials including 5 in Phase 3, breast cancer with 16 active trials including 4 in Phase 3, non-small cell lung cancer (NSCLC) with 15 active trials including 5 in Phase 3, prostate cancer with 8 active trials including 5 in Phase 3, and multiple myeloma with 8 active trials including 4 in Phase 3. Beyond oncology, other therapeutic areas with notable activity include rare disease (10 active trials), immunology (9 active trials), infectious disease (7 active trials), CNS (6 active trials), and metabolic (5 active trials). The significant number of programs in Phase 3 suggests a pipeline with potential near-term catalysts.